BRAIN Biotech AG Elevator Pitch | Strategy & Vision
Investor Snapshot
- COMPANY
- BRAIN Biotech AG
- FORMAT
- Elevator Pitch
- DURATION
- 07:34
- PUBLISHED
- June 2025
- LANGUAGE
- English
In 60 Seconds
CFO Michael Schneiders presents BRAIN Biotech's elevator pitch with focus on enzyme innovation industrial biotech and sustainable production
June 4, 2025
07:34 
Key Takeaways
BRAIN Biotech AG: Elevator Pitch from CFO Michael Schneiders
A Pioneer in Sustainable Industrial Biotechnology
In this compelling elevator pitch from CFO Michael Schneiders of BRAIN Biotech AG, headquartered in Zwingenberg, Germany, the company positions itself as a pioneer in sustainable industrial biotechnology, utilising nature as a blueprint to tackle some of the world’s most pressing industrial production challenges.
Biotechnological Innovation for Global Challenges
BRAIN applies biotechnological principles to improve the efficiency, sustainability, and health impact of industrial production, especially in food, beverage, and life sciences. Its innovations include enzyme solutions that contribute to energy savings, alternative proteins that reduce the need for monocultures and livestock farming, and bio-based ingredients, all of which contribute to global food security and well-being.
Two Core Business Divisions
The company operates via two core divisions:
BRAIN Biocatalysts
A commercial products division generating approx. €47.5 million in annual revenues and €5.1 million in adjusted EBITDA. It focuses on enzymes, microorganisms, and bio-based ingredients used widely in processed food and other industrial applications. The segment is profitable, maintains a strong 5% R&D investment ratio, and aims to reach €100 million in sales with a 15% adjusted EBITDA margin in the medium term, demonstrating strong revenue growth.
BRAIN BioIncubator
The innovation arm is dedicated to incubating high-potential biotech projects, primarily in the space of food, beverage and pharmaceuticals. Last year, it generated €7.1 million in revenue. It is central to the company’s long-term value creation strategy, with a focus on monetising breakthrough technologies and entering high-margin licensing partnerships.
Fully Integrated Enzyme Solutions Provider
BRAIN is a fully integrated enzyme solutions provider covering the entire value chain:
- Discovery (in nature or via own engineering)
- Strain development and expression (bacteria, fungi, or yeast-based bio-factories)
- Fermentation (industrial-scale in Cardiff)
- Enzyme formulation and global distribution
Three Go-to-Market Channels
The company serves customers via three go-to-market channels:
- Product sales: Especially to the food & beverage sectors (dairy, baking, wine, starch)
- Contract research: Custom R&D for client-specific solutions
- Contract development and manufacturing (CDMO): Supporting client bioprocess optimisation and industrial fermentation
High-Value BioIncubator Projects
CFO Schneiders highlights two high-value BioIncubator projects now being commercialised:
Royalty Pharma Transaction
BRAIN monetised early-stage rights to an investigative pharmaceutical compound, securing €18.4 million upfront with potential total proceeds of up to €138 million.
Licensing Deal with Akribion Therapeutics
BRAIN exclusively licensed its proprietary genome editing platform (CRISPR-Cas-like) for therapeutic use in oncology. The deal includes up to €92 million in milestone payments, as well as royalties on net sales.
Ambitious Five-Year Targets
Looking ahead, BRAIN has set ambitious five-year targets:
- Doubling BRAIN Biocatalyst revenue to €100 million
- Reaching 15% adjusted EBITDA margin
- Investing 7–10% of group sales in R&D
- Generating additional revenues and profitability via BioIncubator monetisation
Conclusion: Investing in the Century of Biology
Michael Schneiders concludes with a confident outlook:
“The century of biology has just begun—and with your investment in BRAIN Biotech, you can become part of this megatrend. We are an innovator inspired by nature, with scalable technologies, growing addressable markets, and a clear ambition to become a top 10 enzyme player globally.”
- BRAIN Biotech Can Help to Solve Some of the World‘s Greatest Challenges
- Successful Niche-Player in Research, Development and Production of Enzyme
- BRAIN Biotech Acts as a Solutions Provider Across the Entire Enzyme Value Chain
- BRAINBiocatalysts – Offering Specialty Products and Tailor-Made Solutions
- BRAINBioIncubator – the Commercialization Phase has Already Started
- Our Mid-Term Growth Targets
- Key Messages
This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/
Continuing the Journey: More Presentations
Discover Additional Elevator Pitches
(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG
Unlock the insights of top publicly listed companies with seat11a.com